Patient characteristics
| Patient characteristics | Discovery cohort (n=8) | Validation cohort (n=20) |
| N (%) | N (%) | |
| Age, median (range) | 66 (45–83) | 68.5 (37–82) |
| <65 | 4 (50) | 8 (40) |
| >65 | 4 (50) | 12 (60) |
| Gender | ||
| Female | 3 (37.5) | 6 (30) |
| Male | 5 (62.5) | 14 (70) |
| Response | ||
| CR | 3 (37.5) | 3 (15) |
| PR | 1 (12.5) | 5 (25) |
| SD | 0 (0) | 2 (10) |
| MR | 0 (0) | 2 (10) |
| PD | 4 (50) | 8 (40) |
| PFS | ||
| >6 months | 4 (50) | 11 (55) |
| <6 months | 4 (50) | 9 (45) |
| BRAF status | ||
| WT | 5 (62.5) | 10 (50) |
| V600 | 3 (37.5) | 10 (50) |
| M stage | ||
| M1a | 3 (37.5) | 7 (35) |
| M1b | 3 (37.5) | 5 (25) |
| M1c | 2 (25) | 8 (40) |
| Performance Status, ECOG (0–5) | ||
| 0 | 5 (62.5) | 13 (65) |
| 1 | 3 (37.5) | 6 (30) |
| 2 | 0 (0) | 1 (5) |
CR, complete response; ECOG, Eastern Cooperative Oncology Group; MR, mixed response; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, steady disease; WT, wild type.